Imricor signed distribution agreement to facilitate sales in Australia and NZ
2021-04-01 02:17:50 (AET) by Ring Zhang 527
Imricor Medical Systems (ASX: IMR) signed a Distribution Agreement with Sydney-based medical device distributor Regional Health Care Group Pty Ltd (RGCH). Pursuant to the agreement, RHCG will be the exclusive distributor of Imicor's consumable products in Australia and New Zealand, and a non-exclusive distributor of Imicor's capital equipment.
Imricor Medical Systems (ASX: IMR), an ASX-listed global cardia ablation product producer, has signed a Distribution Agreement with Sydney-based medical device distributor Regional Health Care Group Pty Ltd (RGCH). Pursuant to the agreement, RHCG will be the exclusive distributor of Imicor's consumable products in Australia and New Zealand, and a non-exclusive distributor of Imicor's capital equipment.
Further to that, RHCG will also provide assistance with regulatory approvals in Australia and New Zealand for Imicor's product, with first approvals expected by year-end 2021.
Regional Health Care Group is an Australian-owned business with over 40 years of experience in the medical industry as a provider of medical consumables, contrast media, and capital equipment.
Imricor’s Chair and CEO, Steve Wedan, commented: “We are thrilled to join forces with Regional Healthcare Group to bring Imricor’s products and MRI-guided ablations to Australia and New Zealand. This is an important part of our geographical expansion plans, and we can’t think of a better partner to work with. Together, we look forward to helping improve the care of Australians and New Zealanders struggling with cardiac arrhythmias.”
RHCG General Manager Stephen Doorey added “We are extremely excited to partner with Imricor, their innovative and exciting new solution for Cardiac Ablations is a great addition to our business. RHCG has unrivalled experience in supplying and servicing medical equipment and consumables to the Radiology and Cardiology sector across Australia and New Zealand with over 1,200 devices installed.”
A bit intro about Imricor
Imicor is a leading developer of innovative MRI-compatible medical devices which are used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.
The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.
The share price of IMR moved up by 3.70% to $2.24.
Sources: IMR ASX Announcement